Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Becker Muscular Dystrophy Clinical Presentation

  • Author: Benjamin R Mandac, MD, MD; Chief Editor: Stephen Kishner, MD, MHA  more...
 
Updated: Sep 03, 2015
 

History

A typical developmental history of a patient with BMD may include the following:

  • Delayed gross motor milestones (eg, late walking, running, jumping, difficulty with stair climbing) may be reported.
  • Initially, some children who are later diagnosed with BMD may be called clumsy.
  • Increasing numbers of falls, toe walking, and difficulty rising from the floor may be later features.
  • Proximal muscle weakness is reported.
  • Subclinical cases may manifest later in life; dilated cardiomyopathy can be the first sign of BMD.
  • Elbow contractures may be seen later in life.
Next

Physical

See the list below:

  • The Gower sign is not a specific finding for muscular dystrophy, but it does point to proximal weakness in the hip extensors, leading to the pattern of movement seen when patients rise from the floor.
  • A weakness pattern limited to specific muscle groups may help to differentiate BMD from other muscular dystrophies (such as limb-girdle and Emery-Dreifuss muscular dystrophies).
  • Progressive, symmetrical muscle weakness and atrophy with pseudohypertrophic calves may be seen.
  • Cases have been described of patients presenting without weakness but with symptoms of cardiomyopathy or cramps as the only indication of a myopathic process. Isolated weakness to the quadriceps femoris may be the only symptom noted.
  • Fasciculation or sensory modality abnormalities can exclude the diagnosis of a dystrophinopathy.
  • Preservation of neck flexor muscle strength may differentiate BMD from DMD.
Previous
Next

Causes

BMD is an X-linked, recessive, inherited disorder. A family history of similarly affected maternal uncles assists the clinician in confirming a diagnosis of BMD.

  • A woman is an obligate heterozygote if she has an affected son and one other affected relative in the maternal line.
  • A woman with more than 1 affected child and no family history in the maternal line may have a germline mutation or a germline mosaicism.
  • An isolated proband without a family history may be explained by a mutation occurring in the egg at or following conception in which only some cells were affected (mosaicism). On the other hand, the proband's mother may have inherited the gene mutation if (1) her mother was a carrier or (2) her mother or father had somatic or germline mosaicism.
  • Siblings of the proband are at risk of transmitting the gene defect based on the carrier status of the mother.
    • A carrier mother has a 50% transmission rate for the mutation, per pregnancy; daughters inheriting the mutation will be carriers, and sons with the mutation will be affected.
    • Mothers with germline and/or somatic mosaicism have a higher risk of transmitting the mutation.
Previous
 
 
Contributor Information and Disclosures
Author

Benjamin R Mandac, MD, MD Chief Physical Medicine and Rehabilitation, Medical Director Pediatric Rehabilitation Kaiser Permanente at Santa Clara

Benjamin R Mandac, MD, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kat Kolaski, MD Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine

Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kishner, MD, MHA Professor of Clinical Medicine, Physical Medicine and Rehabilitation Residency Program Director, Louisiana State University School of Medicine in New Orleans

Stephen Kishner, MD, MHA is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Elizabeth A Moberg-Wolff, MD Medical Director, Pediatric Rehabilitation Medicine Associates

Elizabeth A Moberg-Wolff, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

References
  1. Becker PE, Kiener F. [A new x-chromosomal muscular dystrophy.]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1955. 193(4):427-48. [Medline].

  2. Becker PE. Two families of benign sex-linked recessive muscular dystrophy. Rev Can Biol. 1962 Sep-Dec. 21:551-66. [Medline].

  3. Angelini C, Fanin M, Pegoraro E, et al. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord. 1994 Jul. 4(4):349-58. [Medline].

  4. Gurvich OL, Tuohy TM, Howard MT, et al. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol. 2008 Jan. 63(1):81-9. [Medline].

  5. Ashton EJ, Yau SC, Deans ZC, et al. Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene. Eur J Hum Genet. 2008 Jan. 16(1):53-61. [Medline].

  6. Arahata K, Beggs AH, Honda H, et al. Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy. J Neurol Sci. 1991 Feb. 101(2):148-56. [Medline].

  7. Koenig M, Beggs AH, Moyer M, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989 Oct. 45(4):498-506. [Medline]. [Full Text].

  8. Schwartz M, Hertz JM, Sveen ML, et al. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology. 2005 May 10. 64(9):1635-7. [Medline].

  9. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, et al. Restoration of the Dystrophin-associated Glycoprotein Complex After Exon Skipping Therapy in Duchenne Muscular Dystrophy. Mol Ther. 2011 Nov 15. [Medline].

  10. Mavrogeni S, Markousis-Mavrogenis G, Papavasiliou A, Kolovou G. Cardiac involvement in Duchenne and Becker muscular dystrophy. World J Cardiol. 2015 Jul 26. 7 (7):410-4. [Medline].

  11. Nicolas A, Raguenes-Nicol C, Ben Yaou R, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet. 2015 Mar 1. 24 (5):1267-79. [Medline].

  12. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005 Dec. 116(6):1569-73. [Medline]. [Full Text].

  13. Emery AE, Skinner R. Clinical studies in benign (Becker type) X-linked muscular dystrophy. Clin Genet. 1976 Oct. 10(4):189-201. [Medline].

  14. Holloway SM, Wilcox DE, Wilcox A, et al. Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland. Heart. 2007 Oct 11. [Medline].

  15. Young HK, Barton BA, Waisbren S, et al. Cognitive and Psychological Profile of Males With Becker Muscular Dystrophy. J Child Neurol. 2007 Dec 3. [Medline].

  16. Zhang H, Zhu Y, Sun Y, et al. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy. Dis Markers. 2015. 2015:141856. [Medline].

  17. Menezes MP, North KN. Inherited neuromuscular disorders: Pathway to diagnosis. J Paediatr Child Health. 2011 Nov 3. [Medline].

  18. Lim BC, Lee S, Shin JY, Kim JI, Hwang H, Kim KJ, et al. Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet. 2011 Nov. 48(11):731-6. [Medline].

  19. Rutkove SB, Darras BT. Electrical impedance myography for the assessment of children with muscular dystrophy: a preliminary study. J Phys Conf Ser. 2013. 434(1):[Medline]. [Full Text].

  20. Grootenhuis MA, de Boone J, van der Kooi AJ. Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes. 2007. 5:31. [Medline]. [Full Text].

  21. Hayes J, Veyckemans F, Bissonnette B. Duchenne muscular dystrophy: an old anesthesia problem revisited. Paediatr Anaesth. 2008 Feb. 18(2):100-6. [Medline].

  22. Segura LG, Lorenz JD, Weingarten TN, Scavonetto F, Bojanic K, Selcen D, et al. Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Paediatr Anaesth. 2013 Sep. 23(9):855-64. [Medline].

  23. Jenkins HM, Stocki A, Kriellaars D, Pasterkamp H. Breath stacking in children with neuromuscular disorders. Pediatr Pulmonol. 2013 Aug 16. [Medline].

  24. Pouwels S, de Boer A, Leufkens HG, Weber WE, Cooper C, van Onzenoort HA, et al. Risk of fracture in patients with muscular dystrophies. Osteoporos Int. 2013 Aug 15. [Medline].

  25. Duan D. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Curr Opin Mol Ther. 2008 Feb. 10(1):86-94. [Medline].

  26. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector. Mol Ther. 2011 Nov 8. [Medline].

  27. Stöllberger C, Finsterer J. Worsening of heart failure in Becker muscular dystrophy after nonsteroidal anti-inflammatory drugs. South Med J. 2005 Apr. 98(4):478-80. [Medline].

  28. King WM, Kissel JT, Visy D, Goel PK, Matkovic V. Skeletal health in duchenne dystrophy: Bone-size and subcranial DXA analyses. Muscle Nerve. 2013 Jul 24. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.